Loading...
Loading...
UBX| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 216.0K |
| Gross Profit | -216.0K |
| Operating Expense | 6,602.0K |
| Operating I/L | -6,602.0K |
| Other Income/Expense | 121.0K |
| Interest Income | 396.0K |
| Pretax | -6,481.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -6,481.0K |
Unity Biotechnology, Inc. is a biotechnology company specializing in the research and development of therapeutics aimed at addressing age-related diseases. Their lead drug candidate, UBX1325, is in Phase II clinical trial for treating age-related eye diseases such as diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. The company also develops UBX1967 and UBX2050 for ophthalmologic diseases, as well as UBX2089 for multiple neurology indications. Unity Biotechnology, Inc. focuses on creating innovative treatments to slow, halt, or reverse the progression of aging-related illnesses, generating revenue through the sale of these therapeutics.
